Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yellow fever vaccine (17D strain)
- Development stage
- Approved
- Lead developer
- Immunobiological Technology Institute (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz)
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Yellow fever vaccine (17D strain) is a live-attenuated viral vaccine used for active immunization against yellow fever. Originally developed in 1937 by Max Theiler at the Rockefeller Foundation, the vaccine is derived from the wild-type Asibi strain of the yellow fever virus through serial passages in mouse and chicken embryo tissues. This process yielded the attenuated 17D strain, which has since been maintained as three primary substrains: 17D-204, 17DD, and 17D-213. The vaccine is manufactured by culturing these substrains in embryonated chicken eggs. It is highly immunogenic, with a single subcutaneous or intramuscular dose eliciting protective levels of neutralizing antibodies and robust T-cell responses in over 99% of recipients within 30 days, providing lifelong immunity for most individuals. The vaccine is marketed globally under various brand names, including YF-VAX and Stamaril by Sanofi, and is produced by a limited number of WHO-prequalified manufacturers to support global immunization programs and travel prophylaxis.
- Brand names
- ArilvaxStamarilYF-VAX
- Other names
- 17D vaccineyellow fever vaccineyellow fever vaccine (live)yellow fever vaccine liveyellow fever virus strain 17D-204 live antigenyellow fever virus strain 17DD live antigenyellow fever virus vaccine
Beyond the preview
Go deeper on yellow fever vaccine (17D strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yellow fever vaccine (17D strain).